Anyway, the world is full of ironies and JP - as Garnier likes to be known - is now on a mission to mend a few fences before his latest salary package is voted on in May. But it's not just about money ...

“JP brings exceptional operational and leadership experience as BioAge advances its pipeline for metabolic diseases.” Garnier served as the Chief Executive Officer of GlaxoSmithKline ...

BioAge Labs has appointed former GSK CEO Jean-Pierre Garnier as chair of its board of directors, bringing the pharma veteran back into the anti-aging space 16 years after he made a big bet on the ...

All of Investors’ Chronicle’s stock screens: together in one performance dashboard and updated weekly ...

GSK has signed a research collaboration and license agreement worth over US $335 million with the University of Texas MD Anderson Cancer Center, to develop new therapeutic antibodies that promote ...

Purpose: The current indications, dosing, and practical considerations for use of newer anticoagulants in patients with various degrees of renal impairment who do not require dialysis are reviewed ...

Garnier will succeed current Board Chair James Healy, MD, PhD, managing partner of Sofinnova Investments, who will remain on the Board.

Enoxaparin [23] Observe patients with moderate (CL cr of 30-50 mL/min) or mild (CL cr of 50-80 mL/min) renal impairment carefully for signs and symptoms of bleeding. Use with caution in elderly ...